EN
About PDOHub™ HK
Asia’s Organoid Precision Medicine Hub
PDOHub™ Hong Kong is the Asia’s First Integrated Organoid‑Based Precision Medicine Centre, established by BiomOrgan and InnoHK Centre for Virology, Vaccinology, and Therapeutics (CVVT) to bring advanced organoid technology into real‑world applications. We serve as a dedicated hub for developing, validating, and deploying patient‑derived organoid (PDO) platforms across oncology, infectious diseases, and emerging health challenges.
Our Mission & Vision
Mission
To advance patient-derived organoid (PDO) technologies that generate functional, high-resolution insights across diseases, empowering researchers, innovators, and healthcare partners to accelerate discovery, refine therapeutic strategies, and drive translational impact from bench to real-world application.
Vision
To position PDOHub™ HK as Asia’s leading organoid-driven precision medicine centre, delivering scalable, quality-assured, and clinically aligned platforms that redefine how therapies are selected, evaluated, and developed across infectious diseases, oncology, and future emerging health challenges.
Our Leadership & Advisory Board
Dr. Linda Huang
Co-Founder
Chief Scientific Officer, BiomOrgan Limited
Former Scientific Officer, PWH
Former Research Asst. Prof., CUHK
R&D Leader in Cancer Organoid
Mr. Benson To
Co-Founder
Chief Operating Officer, BiomOrgan Limited
Co-Founder & Director of Life science and Logistic Ventures
Clinical & Translational Operations Lead
Prof. Zhou Jie
Scientific Advisor
Founder & Chairman, BiomOrgan Limited
Associate Professor, HKU
Principal Investigator, CVVT
Inventor, Respiratory Organoid Technology
Clarivate Highly Cited Researcher
Prof. Dora Kwong
Honorary Clinical Advisor
Clinical Professor, Department of Clinical Oncology, HKU
MBBS (HK), MD (HK), FRCR, FHKCR, FHKAM (Radiology)
Dr. Zhang Yong
Strategic Advisor
Chief Executive Officer, BiomOrgan Limited
Former Assistant President, BGI
Director, China National GeneBank
Project Leader for ISO’s First Organoid Standard under ISO/TC 276 Biotechnology
Dr. Andrew Lee
Strategic Partner
Assistant Director, CVVT
Oversees Strategic Coordination and Institutional Alignment
Drives Translational Impact Across Biotech Partners
Why PDOHub™
Scientific Rigor
Evidence‑based methodologies refined through over a decade of organoid innovation and development.
Proprietary Tech
Utilizing 3D organoid cultures to generate drug sensitivity insights that support clinician decision‑making.
Clinical Expertise
Developing strong collaborations with healthcare partners to support clinicians with data‑driven, patient‑aligned insights.
Global Partnerships
A trusted partner to biopharma and academia, advancing next‑generation translational organoid innovation.